Brieflands
History
The company was first founded by Seyyed M. Miri and Seyed-M Alavian as an editorial group in a Medical Institute in 2007 to publish its medical journal. After three years of experience, the number of journals increased to 5 journals, and the company launched its first form of business as a VOF (collaboration) professional STM company in Heerlen, the Netherlands, which was called "Kowsarmedical Publishing." Respecting the publishing services (from submission to publishing), especially an in-house "Journal Management System," our journals increased to more than 60 STM journals between 2010 and 2019. Since 2022, "Brieflands" is the new brand name that acts as a "Science, Technical, Medical Publisher" that publishes more than 50 journals with the services provided by 97 expert employees in three different branches.
Business Profile
- Brieflands is a Registered Trademark with record number 1454012.
- Brieflands has been registered as a General partnership (Vennootschap onder firma) company in the Chamber of Commerce (Kamer van Koophandel) of the Netherlands since 2010.
- KvK number: 89235444.
- BTW (VAT) number: NL864918896B01 (check online at VIES)
- RSIN: 864918896
- Nedmedica is our related company which is specialized in Author Services.
- Our former branding name was Kowsarmedical Publishing (2010-2021).

Communities in Brieflands
Select a community to browse its collections.
Recent Submissions
Item type:Item, Comparison of Methadone and Morphine in the Treatment of Neonatal Abstinence Syndrome Based on Treatment Duration(Brieflands, 2026-11-30) ;Ali Naseh ;Kosar Noorzadeh ;Ghazaleh Rasti ;Farzaneh PalizbanFarhad MansouriBackground: Neonatal abstinence syndrome is a major consequence of in utero opioid exposure. Objectives: This study compared methadone and morphine for controlling NAS and assessed their effects on treatment duration. Methods: This prospective comparative clinical trial with alternating allocation was conducted at Mahdiyeh Hospital in 2024 - 2025. Neonates with a gestational age of ≥ 34 weeks who were diagnosed with NAS were assigned to a treatment group. Pharmacologic treatment was initiated when two assessments performed 3 - 4 hours apart yielded Finnegan scores ≥ 8. Neonates with major congenital anomalies were excluded. Treatment duration was measured until treatment cessation. Results: Of 158 neonates, 89 received methadone (mean treatment duration, 19.3 days; median, 17 days; range, 7 - 50 days), and 69 received morphine (mean treatment duration, 21.2 days; median, 20 days; range, 8 - 51 days). Variability was high in both groups, with standard deviations of 9.1 days for methadone and 10 days for morphine. The unadjusted independent-samples t-test showed that treatment lasted an average of 1.9 days longer in neonates receiving morphine; however, the difference was not statistically significant (P = 0.212). In the primary multivariable analysis, which was adjusted for gestational age, birth weight, milk intolerance, and polysubstance exposure but not phenobarbital use, morphine was associated with an estimated 2.05-day longer treatment duration than methadone; this difference was not statistically significant (β = 2.05 days; 95% confidence interval [CI], −1.29 to 5.40; P = 0.229). In a sensitivity analysis additionally adjusted for phenobarbital use, the estimated treatment effect was attenuated and reversed in direction (β = −0.34 days; 95% CI, −3.70 to 3.01; P = 0.841). None of the covariates in the primary model, including gestational age, was independently associated with treatment duration (P > 0.05). Adjunctive phenobarbital use was associated with longer treatment duration. Sex was not associated with treatment duration and was not retained as a significant predictor. Conclusions: No statistically significant difference in treatment duration was observed between methadone and morphine for NAS.Item type:Item, Mapping Psychological Empowerment Interventions for Nurses: A Scoping Review(Brieflands, 2026-12-31) ;Nasrin Rezaee ;Ali Navidian ;Jebreil Balafkan ;Nasrin Rezaee [0000-0002-9236-405X]Ali Navidian [0000-0001-6890-1508]Context: A supportive and empowering work environment plays a vital role in enhancing nurses’ job satisfaction, performance, and retention, as well as organizational effectiveness, ultimately facilitating the delivery of high-quality and safe patient care. This scoping review was undertaken to systematically map and synthesize existing evidence on interventions designed to foster psychological empowerment among nurses and to identify their key characteristics, theoretical frameworks, delivery methods, duration, and outcome measures. Evidence Acquisition: A systematic search was conducted in five databases—PubMed, Scopus, Web of Science, ScienceDirect, and the Cochrane Library—from inception through June 30, 2026, in accordance with the Joanna Briggs Institute methodology. Study selection was guided by predefined eligibility criteria. Completeness of intervention reporting was assessed using the TIDieR checklist, and the extracted data were summarized in tables. Results: Fourteen studies met the inclusion criteria, and thirteen reported the theoretical frameworks used. Interventions were predominantly educational and combined theoretical and practical components. Their duration ranged from 30 – 60 minutes to 10 weeks, and delivery formats included offline, online, and blended approaches. Participants included staff nurses and nurse managers. The Spreitzer Psychological Empowerment Scale was the most frequently used scale. Significant improvement was reported in 7/14 studies, mixed findings were reported in 1/14, and no significant overall change was reported in 6/14. Conclusions: Evidence on psychological empowerment interventions for nurses remains in the early stages. Preliminary, study-reported findings suggest potential positive effects on nurses’ well-being, but evidence regarding patient care is limited. However, the risk of bias was not assessed, and the heterogeneity of study designs and outcomes warrants cautious interpretation. Future research should prioritize randomized controlled trials with larger samples, robust theoretical frameworks, diverse intervention content and delivery, and comprehensive evaluation strategies.Item type:Item, Comparison of Two Preoperative Intravenous Dexmedetomidine Doses (0.1 Versus 1 µg/kg) for Pain and Nausea/Vomiting After Laparoscopic Cholecystectomy: A Randomized Controlled Trial(Brieflands, 2026-08-31) ;Mojtaba Rahimi Varposhti ;Masoud Sayadi ;Behzad Nazemroaya ;Hojatallah SouriMojtaba Rahimi Varposhti [0000-0001-7725-9393]Background: Postoperative pain and nausea and vomiting (PONV) hinder recovery after laparoscopic cholecystectomy. Despite the opioid-sparing and sympatholytic effects of dexmedetomidine, its dose-dependent outcomes remain unclear. Objectives: This randomized trial aimed to compare postoperative pain intensity, rescue analgesic requirements, PONV, hemodynamic outcomes, adverse events, recovery characteristics, and patient satisfaction between patients receiving 1 μg/kg and 0.1 μg/kg intravenous dexmedetomidine, each administered over 10 minutes. The lower-dose regimen was evaluated to assess outcomes with reduced total drug exposure; medication costs were not evaluated. Methods: In this randomized trial, 88 adults were assigned to two groups of 44 participants each. Dexmedetomidine at doses of 1 µg/kg or 0.1 µg/kg was diluted with 0.9% normal saline to a final volume of 20 mL in identical coded syringes and administered intravenously over 10 minutes, beginning 15 minutes before surgery. The primary longitudinal outcome was postoperative pain measured using the visual analogue scale (VAS). The initial analysis used repeated-measures ANOVA, whereas additional covariate-adjusted models were conducted as exploratory analyses. Results: The unadjusted longitudinal visual analogue scale (VAS) analysis did not demonstrate a significant between-group effect (P = 0.675) or a group-by-time interaction (P = 0.217). In an exploratory adjusted generalized estimating equation (GEE) analysis, the mean between-dose VAS contrast, averaged over nine postoperative visits, was 0.20 points (95% CI: -0.28 to 0.68; P = 0.422). The interaction was not statistically significant (Wald χ²(8) = 9.55, P = 0.298). Rescue analgesia was required in 22 of 44 and 15 of 44 patients, respectively (adjusted OR = 0.46; 95% CI: 0.16 to 1.35; P = 0.157). Nausea occurred in 21 of 44 and 14 of 44 patients (adjusted OR = 0.51; 95% CI: 0.16 to 1.64; P = 0.255). Adjusted mean differences were 3.53 mmHg (95% CI: -0.30 to 7.35; P = 0.071) for mean arterial pressure (MAP) and 9.36 minutes (95% CI: 3.76 to 14.97; P = 0.001) for extubation time. All effect comparisons represent 0.1 µg/kg minus 1 µg/kg or the odds for the lower-dose group relative to the higher-dose group. Conclusions: Neither the original longitudinal analysis nor the exploratory covariate-adjusted analyses demonstrated a statistically significant difference in postoperative pain between the doses. As a superiority trial, this study cannot establish analgesic equivalence or noninferiority. The trial compared total dexmedetomidine doses that differed tenfold but did not assess placebo-controlled efficacy.Item type:Item, Efficacy of Cognitive Therapy on Meta-Worry and Experiential Avoidance in Individuals with Panic Disorder(Brieflands, 2026-12-31) ;Nazanin Zahra Ariamanesh ;Rezvan Homaei ;Fariba Zargar Shirazi ;Sadrollah KhosraviZahra Dasht BozorgiBackground: Panic disorder is characterized by recurrent, unexpected panic attacks that are often exacerbated and maintained by cognitive dysfunctions, particularly meta-worry and experiential avoidance. Objectives: This study evaluated the efficacy of cognitive therapy in reducing meta-worry and experiential avoidance among individuals with panic disorder and the short-term maintenance of these effects. Methods: This clinical trial used a pretest-posttest design with a two-month follow-up. A total of 20 patients aged 18 - 45 years with panic disorder were recruited through purposive sampling from psychological clinics in Shiraz, Iran, during 2025. Participants were allocated to an experimental group (n = 10) or a waitlist control group (n = 10). The experimental group received ten 90-minute sessions of protocolized cognitive therapy delivered twice weekly. Data were collected at baseline, postintervention, and follow-up using the Meta-Worry Questionnaire and the Experiential Avoidance Scale. Data were analyzed using repeated-measures analysis of variance. Results: Repeated-measures analysis of variance demonstrated significant time-by-group interaction effects. Compared with the control group, the experimental group showed substantial posttreatment reductions in both meta-worry and experiential avoidance (P < 0.001). These therapeutic gains were sustained within the experimental group at the two-month follow-up. Conclusions: Cognitive therapy reduces transdiagnostic maintenance mechanisms in panic disorder by restructuring catastrophic misinterpretations and enhancing emotional exposure. Sustained improvements relative to the control group highlight its utility as a durable nonpharmacological intervention.Item type:Item, Investigation of the Correlation Between FTIR Spectral Characteristics and Antimicrobial Activity (MIC) of Neem (<i>Azadirachta indica</i>) Extracts Obtained by Different Extraction Methods(Brieflands, 2026-10-31) ;Mohammad Javad AbgharyMarziye RezaeiBackground: Neem (Azadirachta indica) contains diverse bioactive compounds with established antimicrobial properties, and the efficiency of extracting these compounds depends strongly on the solvent polarity. Objectives: This study aimed to investigate the correlation between Fourier-transform infrared (FTIR) spectral characteristics and antimicrobial activity, specifically the minimum inhibitory concentration (MIC), of neem extracts obtained using different extraction solvents. Methods: Neem samples were collected from the Sistan and Baluchestan region, shade-dried, and extracted using different solvents, including ethanol and acetone. Antimicrobial activity against Staphylococcus aureus strains was assessed, and the MIC and minimum bactericidal concentration (MBC) values were determined using the microdilution method. Chemical functional groups were analyzed by FTIR spectroscopy. Results: FTIR analysis identified key functional groups, including hydroxyl (-OH) and carbonyl (C=O) groups. A strong correlation was observed between the intensities of these peaks and antimicrobial potency. The acetone extract exhibited the highest antibacterial activity and showed greater absorption intensity at specific FTIR wavenumbers. Conclusions: Neem antimicrobial activity may be associated with bioactive compounds such as tannins, flavonoids, and terpenoids. These findings indicate that the extraction solvent influences the yield of these compounds and, consequently, antimicrobial efficacy.